Pagnel (Zoledronic Acid)
ZOLEDRONIC ACID
4 mg Lyophilized Powder for Solution for Infusion (I.V)
Bisphosphonate
SUMMARY:
Zoledronic acid is a bisphosphonate used to treat malignancy associated hypercalcemia, multiple myeloma, and bone metastasis from solid tumors.
INDICATION
Zoledronic acid is indicated to treat hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, osteoporosis in men and postmenopausal women, glucocorticoid induced osteoporosis, and Paget's disease of bone in men and women. Zoledronic acid is also indicated for the prevention of osteoporosis in post menopausal women and glucocorticoid induced osteoporosis.
PHARMACODYNAMICS
Absorption : Poorly absorbed orally; administered via IV infusion.
Distribution : Widely distributed; accumulates in bone.
Metabolism : Not metabolized; acts directly on bone.
Elimination: Renal excretion.
Protein Binding: Approximately 43%
Half Life: : 146 hours (long duration of action).
MECHANISM OF ACTION
Inhibits osteoclast-mediated bone resorption, reducing bone turnover.
PHARMACODYNAMICS
Increases bone density and reduces the risk of fractures in osteoporosis.
CAUTIONS
Renal impairment; hypocalcemia; monitor renal function before administration.
METHOD OF ADMINISTRATION
IV infusion.
OVERDOSE AND TREATMENT
Supportive care; monitor renal function and electrolytes.
IN PREGNANCY AND LACTATION
Contraindicated; not studied in pregnancy.
TOXICITY
Osteonecrosis of the jaw; renal toxicity; hypocalcemia.
DOSAGE AND ADMINISTRATIONS
Typically 4 mg IV once a year for osteoporosis.
WHY PAGNEL?
- Effective for the treatment of osteoporosis and certain cancers; long duration of action.
- High quality at lesser cost
